Award
NIH Reporter #5R01AG063826-05
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial
Recipient
Not Specified
Award Amount
$6,580,973.00
Ceiling
$6,580,973.00
Awarded
July 11, 2025
Identifier
5R01AG063826-05
Phase 2 clinical trial funded by the National Institute on Aging to evaluate Allopregnanolone as a regenerative therapeutic for Alzheimer's disease, with a total award amount of approximately $6.58 million.
Description
This project addresses the urgent need to develop therapeutics to delay and treat Alzheimer’s disease (AD). The Phase 2 clinical trial involves a regenerative treatment regimen of Allopregnanolone (Allo) administered over 18 months, including a placebo-controlled period and a delayed-start period. The primary outcome is the rate of change in ADAS-cog14 score after 12 months.